#United States #New York #AeroVironment #Securities Class Action #AVAV

Reminder of Lead Plaintiff Deadline for AeroVironment, Inc. Shareholders

As the deadline for lead plaintiff applications in the AeroVironment, Inc. (NASDAQ: AVAV) lawsuit approaches, institutional investors holding shares during a crucial period need to evaluate their potential involvement. If you were invested between June 25, 2025, and March 10, 2026, you might need to consider your options for recovery.

Background of the Lawsuit

The legal action contends that AeroVironment and certain officials made significantly misleading statements about the company’s largest contract, valued at $1.7 billion, associated with the Satellite Communication Augmentation Resource (SCAR) program. This lawsuit emerges as the U.S. Space Force was shifting towards a multi-vendor acquisition strategy, which eventually led to the termination of the contract.

Shareholders witnessed a stark decline in AVAV’s stock price, dropping from $392.86 prior to the first corrective disclosure to a low of $207.73 after the third corrective statement. That's an alarming loss of more than 47% for investors. The critical deadline to apply as a lead plaintiff is July 27, 2026, which cannot be overlooked.

Implications for Institutional Investors

Pension funds, mutual funds, and other institutional asset managers must carefully consider their fiduciary obligations. The lawsuit raises significant questions regarding whether these entities were aware of the potentially misleading statements made by management about the SCAR program’s viability as a growth driver. Investors with concentrated exposure in the defense sector may need to investigate the potential impact on their portfolios stemming from the corrections disclosed between January and March 2026.

Management portrayed the SCAR program as a lucrative growth opportunity until just weeks before the work order was halted, which raises important fiduciary concerns. ERISA-governed plan fiduciaries should also assess whether they were in possession of public statements that were allegedly misleading and take appropriate actions.

Fiduciary Obligations and Lead Plaintiff Appointments

Investors who have endured substantial documented losses may be best suited for leading the plaintiff role under the Private Securities Litigation Reform Act (PSLRA). Serving as lead plaintiff allows investors to have direct oversight of the litigation's strategy without incurring additional financial obligations, as the counsel fees will be covered from any recovery. Historically, institutional lead plaintiffs tend to achieve larger settlements than those driven by retail investors.

The lawsuit’s intricate nature is underscored by the three phases of corrective disclosures which complicate damage assessments. Institutions that purchased shares post the September 30, 2025, Investor Open House, may find their losses quantified differently than those who bought prior to that date.

Conclusion and Next Steps

This lawsuit highlights the critical role institutional investors play in securities class actions, reinforcing that they ensure robust representation for misled shareholders. As the July 27, 2026, deadline approaches, affected shareholders are urged to evaluate their options carefully and, if necessary, engage with legal professionals to pursue recovery through this lawsuit. For further assistance, interested parties should reach out to Joseph E. Levi, Esq. or contact SueWallSt for institutional recovery options. Don't delay; consider your potential claims before it’s too late.